Logan Capital Management Inc. Decreases Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Logan Capital Management Inc. trimmed its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 57.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,090 shares of the medical research company's stock after selling 20,289 shares during the period. Logan Capital Management Inc.'s holdings in IQVIA were worth $2,965,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in IQV. Synergy Asset Management LLC bought a new position in shares of IQVIA in the 4th quarter worth $33,000. GKV Capital Management Co. Inc. acquired a new position in IQVIA during the 4th quarter valued at about $39,000. Lee Danner & Bass Inc. acquired a new position in IQVIA during the 4th quarter valued at about $44,000. Zions Bancorporation N.A. increased its position in IQVIA by 55.2% during the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after buying an additional 85 shares in the last quarter. Finally, SBI Securities Co. Ltd. acquired a new position in IQVIA during the 4th quarter valued at about $60,000. 89.62% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the company. JPMorgan Chase & Co. reduced their target price on IQVIA from $240.00 to $232.00 and set an "overweight" rating on the stock in a research report on Tuesday, February 18th. Morgan Stanley upped their target price on IQVIA from $245.00 to $250.00 and gave the company an "overweight" rating in a research report on Tuesday, February 11th. Citigroup cut their price objective on IQVIA from $225.00 to $210.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. Stifel Nicolaus cut their price objective on IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a report on Friday, February 7th. Finally, Barclays cut their price objective on IQVIA from $170.00 to $165.00 and set an "equal weight" rating on the stock in a report on Wednesday, May 7th. Eight equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $230.76.

IQVIA Price Performance

IQV stock traded up $2.23 during mid-day trading on Friday, reaching $142.66. 2,227,287 shares of the company's stock were exchanged, compared to its average volume of 1,514,419. The company has a market cap of $24.68 billion, a price-to-earnings ratio of 19.02, a price-to-earnings-growth ratio of 1.99 and a beta of 1.34. The stock's 50 day moving average is $159.83 and its 200 day moving average is $185.72. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a 12-month low of $135.97 and a 12-month high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.63 by $0.07. The company had revenue of $3.83 billion for the quarter, compared to the consensus estimate of $3.77 billion. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. IQVIA's revenue for the quarter was up 2.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.54 earnings per share. On average, research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.